The alternative complement pathway plays a key role in the pathogenesis of IgA nephropathy. Iptacopan specifically binds to factor B and inhibits the alternative pathway. In this phase 3 ...

Changes in complement pathway biomarkers were consistent with selective alternative pathway inhibition, marked by median changes from baseline in the following: Bb plasma: -21.1% with iptacopan vs ...

“The analyses from this study add to the body of evidence that show Factor D inhibition can correct dysregulation of the alternative pathway and ... for multiple complement-mediated diseases.

TSP-1 reduced C3 and C5 cleavage and formation of the membrane attack complex, attenuating complement-mediated injury in AAV models. Complement activation is a relevant driver in the ...

Interim data from Phase 1/2a study demonstrate near complete inhibition in hemolytic activity and functional activity of alternative complement pathway Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) ...

Both result from a problem with a specific part of the immune system called the alternative complement pathway. Both types of C3 glomerulopathy can cause significant kidney disease and have a ...

PASADENA, Calif., April 24, 2024--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced today that it has dosed the first subjects in a Phase 1/2a clinical trial (NCT06209177 ...

Iptacopan is an innovative, first-in-class oral small molecule that reversibly inhibits factor B—a crucial serine protease in the alternative pathway of the complement system. By targeting this ...

SAN DIEGO -- There was a clinically meaningful reduction in proteinuria with iptacopan (Fabhalta), and a confirmed clinical benefit of alternative pathway inhibition, in a rare kidney disorder ...

“ARO-CFB also demonstrated dramatic reductions in measures of alternative complement pathway activation, with mean reductions at or approaching 100% in AH50 and Wieslab AP at multiple dose level ...